Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Ibrutinib or Idelalisib Preferred in Relapsed Patients Over Chemotherapy for CLL.
Advertisement
[the_ad id="32629"]